Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Person › Details

Carlo Rosa (DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA))

Rosa, Carlo (DiaSorin 201607 CEO)

 

Organisation Organisation DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA)
  Group DiaSorin (Group)
Product Product diagnostics (medical/biological)
     

DiaSorin S.p.A.. (7/28/16). "Press Release: DiaSorin Starts Selling Vitamin D Test in Japan". Saluggia.

DiaSorin (FTSE Italy Mid Cap: DIA) is pleased to announce the start of sales of its CLIA 25 OH Vitamin D test in Japan, following the approval of the reimbursement code from the Japanese authorities.

DiaSorin will be the first company to market the Vitamin D test on its LIAISON analyzers family in the Japanese reference laboratories through an exclusive distribution agreement with Kyowa Medex, part of the Japanese Kyowa Hakko Kirin Group, a company that produces and markets diagnostic reagents. Japan, with a population of over 125 million inhabitants, has about 13 million patients suffering from osteoporosis for whom it will be possible to identify the Vitamin D deficiency in human serum through the DiaSorin test.

As already announced during the presentation of the 2015-2017 Industrial Plan, DiaSorin estimates a market penetration for its CLIA 25 OH Vitamin D test in Japan between 2% and 4% within the next five years, for a total amount between 2.5 and 5 million tests.

"With the approval of the reimbursement for the Vitamin D test in Japan, we confirm our commitment to develop the Vitamin D market”, commented Carlo Rosa, CEO of the DiaSorin Group. “As leader in Vitamin D testing, I’m sure that our Group will be able to seize this opportunity in an effective way, as already demonstrated in the past in other countries”.


About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the Diagnostic field. For over 40 years, the Company has been investing to develop, produce and sell tests that answer to the worldwide laboratories’ needs. The continous focus on innovation enables the DiaSorin Group to be identified as “the Diagnostic specialist”.

For further information, please visit www.diasorin.com


For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it

   
Record changed: 2019-06-06

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px


More documents for Carlo Rosa


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top